Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patientsSophie A. Kurk, Anne M. May, Manuel L. R. Tjin‐A‐Ton et al.|Journal of Cachexia Sarcopenia and Muscle|2019Cited by 107
Trajectories of health-related quality of life and psychological distress in patients with colorectal cancer: A population-based studySeyed M. Qaderi, Ankie M.T. van der Velden, J. Van Der Heijden et al.|European Journal of Cancer|2021Cited by 55
Transanal total mesorectal excision and low anterior resection syndromeJ. Van Der Heijden, Manuel L. R. Tjin‐A‐Ton, Seyed M. Qaderi et al.|British journal of surgery|2021Cited by 22
Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)Patricia A. H. Hamers, Agnès J. van de Wouw, Geraldine R. Vink et al.|Clinical Colorectal Cancer|2022Cited by 16
Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients.Sophie A. Kurk, Anne M. May, Petra H.M. Peeters et al.|Journal of Clinical Oncology|2017Cited by 6